VTE Prevention, Diagnosis, and Acute Lower-Extremity DVT

52.1Why prophylaxis and acute treatment share a chapter

Venous thromboembolism is common enough that every vascular surgeon must treat it as both a daily prevention problem and an acute diagnostic problem. In adult populations in high-income settings, venous thromboembolism is the third most common cardiovascular emergency, with population-based incidence of approximately 1 to 2 per 1000 person-years; that incidence rises sharply with age, surgery, immobility, and cancer WORCESTER Spencer · 2006 · Deep vein thrombosis 2004 · AHA 2024 · Epidemiology venous thromboembolism. 2015 · Risk Factors Venous 2003. The figures are useful for perspective, but the bedside implication is more important: hospitalized, post-operative, immobile, and oncologic patients are not “average-risk” members of the population. They are the group in whom failure to assess risk, prescribe prophylaxis, and reassess bleeding risk creates preventable morbidity.

The trainee’s task is not to memorise every thrombosis trial. The practical task is to decide, for a specific patient on a specific day, whether thrombosis risk is high enough to justify prophylaxis, whether bleeding risk changes the method of prophylaxis, whether symptoms demand diagnostic testing, and whether confirmed thrombosis requires anticoagulation alone or urgent escalation. Prevention and acute treatment therefore belong together: the same clinical variables—recent surgery, cancer, immobility, renal function, age, bleeding history, antiplatelet exposure, and expected life expectancy—determine both the prophylaxis plan and the safety of treatment once DVT occurs ASH 2019 · ASH 2018 · Nicolaides Consensus · 2018 · Prevention VTE Orthopedic 2012 · GARFIELD VTE Weitz 2020 · GARFIELD VTE Weitz · 2019 · Warkentin Vth Extended · 2018 · IMPROVE bleeding risk 2011 · IMPROVE bleeding risk 2011 · Venous thromboembolism risk 2008 · RIETE Lopezjimenez · 2008 · Padua score 2010 · Caprini risk-assessment model 2005 · Caprini risk-assessment model 2005.

A useful mental model is to separate venous thrombosis care into immediate safety, primary treatment, and secondary prevention. The acute phase establishes effective anticoagulation safely; the primary treatment phase prevents extension and embolisation over approximately 3 months; the secondary prevention phase asks whether continued anticoagulation is justified by recurrence risk and bleeding risk ASH 2020 · Kearon Acutephase · 2012. That structure prevents two common errors: stopping too early after a true acute DVT, and continuing indefinitely without revisiting whether the index event was transiently provoked, unprovoked, or cancer-associated.

The caveat is that venous thromboembolism is never managed by a single rule. A patient with a high Caprini score after major surgery may still require mechanical prophylaxis rather than pharmacologic prophylaxis during active bleeding. A patient with iliofemoral DVT may still be best treated with anticoagulation alone if symptoms are tolerable, bleeding risk is high, or life expectancy is limited. A patient with proximal DVT may need compression for edema and pain, but routine stockings to prevent post-thrombotic syndrome are not supported by the SOX trial and pooled data Antithrombotic Therapy VTE 2021 · Cochrane Kahn Compression · 2014 · Compression stockings prevent 2014 · Kahn Postthrombotic · 2014. The senior habit is to document both sides of the decision: why the clot risk is important and why the chosen intervention is safe enough.

Prophylaxis and acute treatment share a chapter because the same patient can move from prevention to diagnosis to therapeutic anticoagulation; the structure is clinical workflow, not a separate decision aid task. AHA 2024 · Kearon Acutephase · 2012

52.2Risk-assessment scores: Caprini, Padua, IMPROVE

Risk assessment should be performed for every adult surgical, trauma, and acutely ill medical inpatient, and it should be documented in a way that explains the prophylaxis order. In surgical and trauma patients, the Caprini risk-assessment model is the dominant scoring instrument; a score of 5 or above classifies the patient as high risk in pooled validation studies and should usually trigger pharmacologic prophylaxis if bleeding risk permits ASH 2019 · Nicolaides Consensus · 2018 · Prevention VTE Orthopedic 2012 · Caprini risk-assessment model 2005 · Caprini risk-assessment model 2005. The vascular surgery resident should not use the score as a substitute for judgment, but as a structured way to make judgment visible: recent operation, immobility, cancer, previous VTE, age, and thrombophilia belong in the note because they explain the order set.

In acutely ill medical inpatients, the Padua Prediction Score and the IMPROVE instruments serve complementary purposes. A Padua score of 4 or more identifies high VTE risk and supports pharmacologic prophylaxis, while the IMPROVE bleeding score helps identify patients in whom bleeding risk should move the plan toward mechanical prophylaxis rather than anticoagulant prophylaxis ASH 2019 · ASH 2018 · IMPROVE bleeding risk 2011 · Venous thromboembolism risk 2008 · Padua score 2010. This distinction matters. A high clot-risk score does not erase bleeding risk, and a high bleeding-risk score does not mean doing nothing; it means using the safest effective substitute while reassessing the patient as bleeding risk changes.

The minimum acceptable documentation is not “DVT prophylaxis: yes.” A useful note states the patient category, the risk score or risk features, the bleeding-risk features, the method chosen, and the date for reassessment. For example: “High VTE risk by Caprini score ≥5 after major operation; no active bleeding; LMWH prophylaxis ordered.” Or: “High medical-inpatient VTE risk by Padua score ≥4; high bleeding risk by clinical factors and IMPROVE framework; intermittent pneumatic compression ordered until bleeding risk improves.” This style of documentation is defensible because it links the decision to the patient’s changing physiology rather than to a static admission order ASH 2019 · ASH 2018 · Nicolaides Consensus · 2018 · Prevention VTE Orthopedic 2012 · GARFIELD VTE Weitz 2020 · GARFIELD VTE Weitz · 2019 · Warkentin Vth Extended · 2018 · IMPROVE bleeding risk 2011 · IMPROVE bleeding risk 2011 · Venous thromboembolism risk 2008 · RIETE Lopezjimenez · 2008 · Padua score 2010 · Caprini risk-assessment model 2005 · Caprini risk-assessment model 2005.

Mechanical prophylaxis should be the default substitute when bleeding risk is high or active bleeding precludes pharmacologic prophylaxis in hospitalized medical or surgical patients ASH 2019 · ASH 2018 · IMPROVE bleeding risk 2011. At the bedside, that means the resident must check whether the devices are actually on the patient, whether the patient can tolerate them, and whether local contraindications such as severe peripheral arterial disease or skin breakdown make intermittent pneumatic compression unsuitable. Mechanical prophylaxis is not a symbolic order; poor adherence converts it into no prophylaxis.

Scores are also a communication tool across services. Vascular surgery patients often move between the operating room, intensive care unit, ward, imaging suite, and rehabilitation setting. A Caprini, Padua, or IMPROVE-based note allows the next clinician to see why anticoagulant prophylaxis was started, held, or changed to mechanical prophylaxis ASH 2019 · ASH 2018 · Nicolaides Consensus · 2018 · Prevention VTE Orthopedic 2012 · IMPROVE bleeding risk 2011 · Venous thromboembolism risk 2008 · Padua score 2010 · Caprini risk-assessment model 2005 · Caprini risk-assessment model 2005. The best residents reassess the score logic after reoperation, bleeding, new cancer diagnosis, prolonged bed rest, or transition to discharge planning.

At the bedside, document the indication, timing, and escalation trigger before choosing surveillance, imaging, intervention, or deferral.

Caprini, Padua, and IMPROVE are best used as prose prompts: identify the patient group, estimate VTE risk, estimate bleeding risk, and choose pharmacologic or mechanical prophylaxis accordingly. IMPROVE bleeding risk 2011 · Padua score 2010

52.3Pharmacologic prophylaxis: LMWH first, DOACs selectively

For most hospitalized patients who merit pharmacologic prophylaxis and do not have prohibitive bleeding risk, low-molecular-weight heparin is the default practical choice. In acutely ill medical inpatients, LMWH prophylaxis reduced symptomatic venous thromboembolism compared with placebo in landmark trials, and current guidance places LMWH and fondaparinux at the center of inpatient pharmacologic prophylaxis ASH 2018 · Prevention Venous Thromboembolism. 2008 · Randomized Placebo-Controlled Trial 2004 · MEDENOX 1999. MEDENOX randomized approximately 1,100 acutely ill medical inpatients aged forty years of age or older to enoxaparin prophylaxis versus placebo for 14 days and established LMWH as a trial-validated center of inpatient medical prophylaxis, with only a small absolute excess of major bleeding.

The practical constraints are bleeding risk and renal function. If bleeding risk is high, intermittent pneumatic compression is preferred until pharmacologic prophylaxis becomes safe ASH 2019 · ASH 2018 · IMPROVE bleeding risk 2011. If renal function is impaired, the resident must not simply accept a default dose without review; renal impairment requires dose adjustment or an alternative plan because anticoagulant exposure can accumulate Prevention Venous Thromboembolism. 2008 · Randomized Placebo-Controlled Trial 2004 · MEDENOX 1999. The daily question on rounds is therefore: “Does this patient still need prophylaxis, and is the current method still the safest method?”

Direct oral anticoagulants have changed acute VTE treatment, but they should be used selectively in the prophylaxis context described here. The supplied evidence base for routine inpatient medical prophylaxis remains centred on LMWH and fondaparinux, and the safe use of any oral anticoagulant requires review of renal function, bleeding risk, drug interactions, and reversibility planning Antithrombotic Therapy VTE 2021 · ASH 2020 · ASH 2018 · Prevention Venous Thromboembolism. 2008 · JAMA 2014 · Direct oral anticoagulants 2014 · Treatment Acute Venous 2014 · AMPLIFY 2013 · HOKUSAI 2013 · EINSTEIN 2010 · Dabigatran versus Warfarin 2009 · Randomized Placebo-Controlled Trial 2004 · MEDENOX 1999 · Kearon Acutephase · 2012. In a vascular surgery service, DOAC exposure also creates perioperative complexity: urgent reoperation, neuraxial procedures, wound bleeding, and unplanned interventions are easier to manage when the prophylaxis plan has been chosen deliberately rather than by habit.

Cancer deserves separate attention because the distinction between prophylaxis and treatment can blur. In patients with active cancer and established acute VTE, long-course LMWH was historically established as preferable to warfarin by CLOT, which randomized 672 patients with cancer-associated VTE to dalteparin for 6 months versus warfarin and showed less recurrent VTE without an increase in major bleeding ASH 2020 · Low-Molecular-Weight Heparin 2003. That treatment evidence should not be misused to justify indiscriminate prophylaxis, but it should make the surgeon alert: active cancer substantially raises thrombotic risk, and once thrombosis is confirmed, cancer-associated treatment choices differ from routine non-cancer VTE.

The complication a trainee must anticipate is not only bleeding; it is prophylaxis failure caused by poor execution. Orders are missed around procedures, mechanical devices are left off during transfers, renal function changes without dose review, and patients judged “ambulatory” may still spend nearly all day in bed. Because VTE risk rises with surgery, immobility, age, and cancer, the resident should reassess prophylaxis after each operation, each bleeding event, each change in renal function, and each major change in mobility ASH 2019 · ASH 2018 · Nicolaides Consensus · 2018 · Prevention VTE Orthopedic 2012 · IMPROVE bleeding risk 2011 · Venous thromboembolism risk 2008 · WORCESTER Spencer · 2006 · Deep vein thrombosis 2004 · AHA 2024 · Epidemiology venous thromboembolism. 2015 · Padua score 2010 · Caprini risk-assessment model 2005 · Caprini risk-assessment model 2005 · Risk Factors Venous 2003.

It is important not to confuse prophylaxis with invasive thrombus removal. Catheter-directed or pharmacomechanical thrombolysis is not prophylaxis and is not a routine alternative to anticoagulation. In ATTRACT, 692 patients with acute proximal DVT were randomized to pharmacomechanical catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone; the intervention did not reduce post-thrombotic syndrome overall at 24 months and produced a significant excess of major bleeding, although an iliofemoral subgroup showed a modest reduction in moderate-to-severe post-thrombotic syndrome Editor's Choice European 2021 · Antithrombotic Therapy VTE 2021 · ASH 2020 · ATTRACT 2017 · Post-thrombotic syndrome after 2016 · Long-term outcome after 2012. CaVenT, in 209 patients with first-time iliofemoral DVT, reported a 14 percentage-point absolute reduction in post-thrombotic syndrome at two years with a bleeding-cost signal and no intracranial hemorrhage. Current practice should therefore reserve catheter-based or surgical thrombus removal for selected patients with severe symptoms, iliofemoral burden, low bleeding risk, and good expected life expectancy; limb-threatening phlegmasia is an urgent exception outside the ordinary trial frame.

For inpatients, prophylaxis is chosen by matching VTE risk, bleeding risk, mobility, renal function, and procedure context; LMWH remains the default pharmacologic reference point when bleeding risk permits. Editor's Choice European 2021

52.4Diagnosing acute lower-extremity DVT

Diagnosis begins with pretest probability, not with a reflex ultrasound order. In an outpatient with suspected lower-extremity DVT, the modified Wells score divides patients into “unlikely” and higher-probability categories; a score of 1 or less combined with a negative sensitive D-dimer rules out DVT without imaging in most patients Editor's Choice European 2021 · ASH 2018 · DVT 2003. This is most useful when symptoms are mild or nonspecific and the patient is not already in a group where D-dimer specificity is poor.

When the Wells score is higher or the D-dimer is positive, compression ultrasound is the diagnostic reference point Editor's Choice European 2021 · ASH 2018 · DVT 2003. For the vascular trainee, the important point is to ask the ultrasound question correctly. Suspected proximal DVT, calf symptoms, recurrent thrombosis, and iliofemoral symptoms are not identical clinical problems. The note should document the pretest probability, the D-dimer result if used, the ultrasound result, and whether the study answers the clinical question that prompted testing.

D-dimer is not a universal gatekeeper. Its specificity falls in inpatients, patients with cancer, pregnancy, and older age; in those groups, a positive result is often not helpful, and an age-adjusted cutoff or higher pretest threshold may be appropriate Editor's Choice European 2021 · ASH 2018 · DVT 2003. In a hospitalized vascular patient after an operation, D-dimer commonly reflects inflammation, tissue injury, or malignancy rather than DVT. The resident should avoid delaying ultrasound in a high-probability inpatient simply to obtain a test that is likely to be positive and non-discriminating.

The clinical examination still matters, but it is insufficient alone. Unilateral swelling, pain, venous congestion, tenderness, new collateral veins, or disproportionate edema should prompt structured assessment. Conversely, bilateral edema in a frail inpatient may have many competing explanations. The value of the Wells-plus-D-dimer strategy is that it protects low-risk outpatients from unnecessary imaging while preserving ultrasound for patients whose probability or laboratory result warrants it Editor's Choice European 2021 · ASH 2018 · DVT 2003.

Documentation should be explicit because anticoagulation and procedural decisions often follow quickly. A good diagnostic note reads: “Suspected left lower-extremity DVT. Modified Wells score ≤1 and sensitive D-dimer negative; DVT ruled out without imaging.” Or: “Wells score above unlikely threshold / D-dimer positive; compression ultrasound ordered.” Or: “Inpatient with cancer and high clinical suspicion; D-dimer not used because specificity expected to be poor; compression ultrasound ordered.” This style shows the attending that the resident understands both the algorithm and its limitations Editor's Choice European 2021 · ASH 2018 · DVT 2003.

52.5Acute anticoagulation: DOACs are first-line for most patients

Once acute lower-extremity DVT is confirmed, anticoagulation should be started promptly unless bleeding risk or another contraindication prevents it. For most adult patients with acute VTE who are eligible for oral anticoagulation, direct oral anticoagulants are first-line therapy. Across contemporary evidence and society guidance, rivaroxaban, apixaban, edoxaban, and dabigatran are non-inferior to LMWH followed by warfarin for acute VTE treatment and are associated with lower major bleeding in pooled analyses; guidance favours DOACs over LMWH-then-vitamin-K-antagonist therapy for most non-cancer VTE patients without antiphospholipid syndrome, mechanical heart valves, severe renal impairment, or pregnancy Antithrombotic Therapy VTE 2021 · ASH 2020 · JAMA 2014 · Direct oral anticoagulants 2014 · Treatment Acute Venous 2014 · AMPLIFY 2013 · HOKUSAI 2013 · EINSTEIN 2010 · Dabigatran versus Warfarin 2009 · Kearon Acutephase · 2012.

The first prescription should include the loading or lead-in logic, not merely the drug name. AMPLIFY randomized 5,395 adults with acute symptomatic VTE to oral apixaban, using 10 mg twice daily as a lead-in followed by 5 mg twice daily, versus enoxaparin followed by warfarin for 6 months; apixaban was non-inferior for recurrent VTE and significantly reduced major bleeding Antithrombotic Therapy VTE 2021 · ASH 2020 · JAMA 2014 · Direct oral anticoagulants 2014 · Treatment Acute Venous 2014 · AMPLIFY 2013 · HOKUSAI 2013 · EINSTEIN 2010 · Dabigatran versus Warfarin 2009 · Kearon Acutephase · 2012. HOKUSAI-VTE randomized 8,240 adults with acute symptomatic VTE to edoxaban after a parenteral lead-in versus warfarin and showed non-inferior recurrent VTE with less clinically relevant bleeding over 3 to 12 months follow-up. The resident must know whether the selected drug is a single-drug strategy from day 1 or requires initial parenteral anticoagulation.

The contraindication check is as important as the diagnosis. DOACs are not appropriate for mechanical heart valves or triple-positive antiphospholipid syndrome, and severe renal impairment and pregnancy remain major exclusions from routine DOAC-first practice Antithrombotic Therapy VTE 2021 · ASH 2020 · JAMA 2014 · Direct oral anticoagulants 2014 · Treatment Acute Venous 2014 · AMPLIFY 2013 · HOKUSAI 2013 · EINSTEIN 2010 · Dabigatran versus Warfarin 2009 · Kearon Acutephase · 2012. Bleeding risk attaches to every anticoagulation choice, so renal function, prior bleeding, recent surgery, antiplatelet co-therapy, age, and weight should be reviewed before the order is signed GARFIELD VTE Weitz 2020 · GARFIELD VTE Weitz · 2019 · Warkentin Vth Extended · 2018 · IMPROVE bleeding risk 2011 · IMPROVE bleeding risk 2011 · RIETE Lopezjimenez · 2008. A vascular service should also make a reversibility plan explicit, especially when the patient may require urgent operation or intervention.

Cancer-associated VTE requires more individualised judgment. CLOT established dalteparin for 6 months as more effective than warfarin in reducing recurrent VTE in cancer-associated thrombosis without increasing major bleeding ASH 2020 · Low-Molecular-Weight Heparin 2003. Later trials of direct oral factor Xa inhibitors showed that edoxaban, rivaroxaban, and apixaban can be non-inferior or superior to LMWH for recurrence, but bleeding risk is tumor-type dependent, especially in gastrointestinal and genitourinary cancers Antithrombotic Therapy VTE 2021 · Caravaggio 2020 · HOKUSAI 2018 · Comparison Oral Factor 2018 · Tinzaparin vs Warfarin 2015. Caravaggio randomized 1,170 patients with cancer-associated VTE to apixaban versus dalteparin for 6 months and showed non-inferior recurrence with comparable major bleeding, supporting apixaban as an option even while drug interactions and platelet counts remain practical constraints.

Most acute lower-extremity DVT is treated with anticoagulation alone. Catheter-based therapy should not be offered simply because clot is present. ATTRACT showed no overall reduction in post-thrombotic syndrome at two years after pharmacomechanical catheter-directed thrombolysis for proximal DVT and showed more major bleeding, while CaVenT suggested benefit in selected first-time iliofemoral DVT patients at the cost of bleeding Editor's Choice European 2021 · Antithrombotic Therapy VTE 2021 · ASH 2020 · ATTRACT 2017 · Post-thrombotic syndrome after 2016 · Long-term outcome after 2012. The practical threshold for invasive thrombus removal is severe iliofemoral symptoms, low bleeding risk, good expected life expectancy, and a realistic chance that early symptom relief or reduction in moderate-to-severe post-thrombotic morbidity justifies the hazard; phlegmasia with limb threat is treated urgently and should not be forced into the ordinary elective selection framework.

Compression should be prescribed for symptoms, not as a reflex to prevent post-thrombotic syndrome. The SOX trial randomized 806 patients with proximal DVT to active 30–40 mmHg stockings versus placebo stockings for two years and did not show a significant reduction in post-thrombotic syndrome, recurrent VTE, or quality of life Antithrombotic Therapy VTE 2021 · Cochrane Kahn Compression · 2014 · Compression stockings prevent 2014 · Kahn Postthrombotic · 2014. A Cochrane review pooling trials including SOX similarly did not identify a clinically significant reduction in post-thrombotic syndrome incidence, supporting selective use in patients with persistent swelling, pain, or established post-thrombotic symptoms rather than routine prescription after every proximal DVT. The resident should reassess edema and symptoms after the acute period rather than equating stockings with disease-modifying therapy.

52.6Duration of anticoagulation and extended therapy

Duration begins with classification of the index event. A DVT provoked by a transient risk factor is generally treated for 3 months; an unprovoked DVT is treated for at least 3 months with extended therapy considered; cancer-associated VTE is treated while the cancer remains active and the balance of recurrence and bleeding risk supports continued therapy Antithrombotic Therapy VTE 2021 · ASH 2020 · EINSTEIN 2017 · AMPLIFY 2013 · Extended Use Dabigatran 2013 · Warkentin Vth Extended · 2018 · Predicting disease recurrence 2012 · VIENNA Eichinger · 2010 · Identifying unprovoked thromboembolism 2008. This is why the discharge summary must identify the event as transiently provoked, unprovoked, or cancer-associated. Without that classification, the next clinician cannot tell whether stopping at 3 months is planned good care or accidental undertreatment.

The 3-month visit is a formal decision point, not an administrative refill. By that time the acute phase has established safe anticoagulation, and primary treatment has reduced the risk of extension and embolisation; the remaining question is secondary prevention ASH 2020 · Kearon Acutephase · 2012. At that visit, the surgeon should review the provoking factor, residual symptoms, bleeding events, renal function, new operations, cancer status, patient values, and the feasibility of continued anticoagulation. The decision should be documented as a recurrence-risk versus bleeding-risk judgment rather than as “continue indefinitely.”

For extended therapy, reduced-dose direct oral anticoagulation has strong support in appropriately selected patients. EINSTEIN CHOICE randomized patients who had completed 6 to 12 months follow-up of anticoagulation for VTE to rivaroxaban 20 mg daily, rivaroxaban 10 mg daily, or aspirin 100 mg daily, and both rivaroxaban doses significantly lowered recurrent VTE compared with aspirin with major bleeding rates similar to aspirin Antithrombotic Therapy VTE 2021 · ASH 2020 · EINSTEIN 2017 · AMPLIFY 2013 · Extended Use Dabigatran 2013 · Warkentin Vth Extended · 2018 · Predicting disease recurrence 2012 · VIENNA Eichinger · 2010 · Identifying unprovoked thromboembolism 2008. This supports reduced-dose rivaroxaban as an extension strategy in patients whose recurrence risk justifies continued therapy and whose bleeding risk is acceptable.

Risk-prediction tools can help structure the extended-therapy discussion after a first unprovoked VTE. The DASH score uses D-dimer, age, sex, and hormonal therapy variables to estimate annualised recurrence risk; a low score identifies patients in whom stopping anticoagulation after 3 months may carry an acceptable recurrence rate, while higher scores support a discussion of extended therapy ASH 2020 · Predicting disease recurrence 2012. These tools do not replace judgment. They are most useful when the patient is not clearly in a very-low-risk or very-high-risk group and when the clinician needs a transparent way to explain uncertainty.

Bleeding risk must be revisited whenever therapy is extended. Major bleeding is the dominant safety endpoint for prophylaxis and treatment decisions, and prediction tools such as IMPROVE, together with individual factors including previous bleeding, recent surgery, antiplatelet co-therapy, renal impairment, age, and weight, should be reviewed alongside recurrence risk GARFIELD VTE Weitz 2020 · GARFIELD VTE Weitz · 2019 · Warkentin Vth Extended · 2018 · IMPROVE bleeding risk 2011 · IMPROVE bleeding risk 2011 · RIETE Lopezjimenez · 2008. The vascular surgeon should be especially careful around staged operations, reinterventions, wounds, and antiplatelet therapy. A patient who was an excellent DOAC candidate at diagnosis may become a poor candidate after renal deterioration or a new bleeding event.

Finally, post-thrombotic symptoms need their own follow-up plan. The SOX trial followed patients with proximal DVT for two years and found no clinically significant prevention of post-thrombotic syndrome with active compression stockings compared with placebo stockings Antithrombotic Therapy VTE 2021 · Cochrane Kahn Compression · 2014 · Compression stockings prevent 2014 · Kahn Postthrombotic · 2014. Current practice is therefore selective: reassess symptoms and edema approximately 1 to 3 months after diagnosis, use compression for persistent swelling or discomfort, and avoid presenting stockings as mandatory disease prevention after every proximal DVT. This is a good example of mature vascular care: treat the patient’s symptoms, but do not overstate an intervention’s preventive effect.

Duration decisions are merged into the acute-treatment table so readers see drug choice and stop/extend decisions together. Antithrombotic Therapy VTE 2021 · EINSTEIN 2017